Radius Health Reports Second Quarter 2016 Financial and Operating Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St set for muted open as Middle East tensions curb risk appetite
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Maxim Group Downgrades Radius Health (RDUS) to Sell
August 4, 2016 2:15 PM EDTMaxim Group downgraded Radius Health (NASDAQ: RDUS) from Hold to Sell with a price target of $24.00.
Analyst Jason McCarthy commented:
RDUS is "back" to an overvalued state. As such we are downgrading to Sell, from Hold. While we continue to believe that Abaloparatide-SC (and eventually the transdermal patch) will likely gain approval in 2017 in both the U.S. (PDUFA March 30, 2017) and Europe (EMA opinion early 2017), we believe significant challenges lay ahead in penetrating a mature Forteo Market, competition from Biosimilar Forteo in 2018 (from Teva [TEVA-$53.57-Buy]) and patients opting for alternative... MoreRadius Health (RDUS) Misses Q2 EPS by 6c
August 4, 2016 6:44 AM EDTRadius Health (NASDAQ: RDUS) reported Q2 EPS of ($1.01), $0.06 worse than the analyst estimate of ($0.95).
For earnings history and earnings-related data on Radius Health (RDUS) click here.
... More